Privileged scaffolds as MAO inhibitors: Retrospect and prospects

AC Tripathi, S Upadhyay, S Paliwal, SK Saraf - European Journal of …, 2018 - Elsevier
This review aims to be a comprehensive, authoritative, critical, and readable review of
general interest to the medicinal chemistry community because it focuses on the …

Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders

B Kumar, AK Mantha, V Kumar - RSC advances, 2016 - pubs.rsc.org
Monoamine oxidase (MAO) enzyme catalyzes the oxidative deamination of xenobiotic and
endogenous amines including many neurotransmitters. The MAO enzyme exists in two …

Integrated approach to structure-based enzymatic drug design: molecular modeling, spectroscopy, and experimental bioactivity

B Honarparvar, T Govender, GEM Maguire… - Chemical …, 2014 - ACS Publications
Analysis of the literature involving computational modeling of diseases and drug design with
the aid of experimental spectroscopic techniques reveals that this specific combination of …

Present status of quinoxaline motifs: Excellent pathfinders in therapeutic medicine

OO Ajani - European journal of medicinal chemistry, 2014 - Elsevier
Quinoxalines belong to a class of excellent heterocyclic scaffolds owing to their wide
biological properties and diverse therapeutic applications in medicinal research. They are …

A perspective on monoamine oxidase enzyme as drug target: challenges and opportunities

B Kumar, V Prakash Gupta, V Kumar - Current drug targets, 2017 - ingentaconnect.com
The monoamine oxidase (MAO) enzyme is responsible for the deamination of monoamine
neurotransmitters and regulates their concentration in the central and peripheral nervous …

Challenging the anticolorectal cancer capacity of quinoxaline-based scaffold via triazole ligation unveiled new efficient dual VEGFR-2/MAO-B inhibitors

MS Ayoup, A Ammar, H Abdel-Hamid, A Amer… - Bioorganic …, 2024 - Elsevier
Monoamine oxidases (MAOs) and vascular endothelial growth factor receptor-2 (VEGFR-2)
are promoters of colorectal cancer (CRC) and central signaling nodes in epithelial …

Exploring new selective 3-benzylquinoxaline-based MAO-A inhibitors: design, synthesis, biological evaluation and docking studies

SN Khattab, SAHA Moneim, AA Bekhit… - European journal of …, 2015 - Elsevier
In this investigation, we searched for novel MAO-A inhibitors using a 3-benzylquinoxaline
scaffold based on our earlier findings. Series of N′-(3-benzylquinoxalin-2-yl) …

Recent advances in the synthesis of biologically active cinnoline, phthalazine and quinoxaline derivatives

Y Taek Han, JW Jung, NJ Kim - Current Organic Chemistry, 2017 - ingentaconnect.com
In the recent decades, N-heterocycles are widely used as versatile scaffolds for the
development of biologically active compounds and considered as one of the privileged …

Design, synthesis and biological evaluation of novel 1, 2, 4-triazolo and 1, 2, 4-triazino [4, 3-a] quinoxalines as potential anticancer and antimicrobial agents

DAE Issa, NS Habib, AEA Wahab - MedChemComm, 2015 - pubs.rsc.org
In an effort to find new leads as anticancer or antimicrobial agents, the present work deals
with the synthesis of some novel 1-substituted 1, 2, 4-triazolo [4, 3-a] quinoxalines 7, 9a, b …

Design, synthesis, and biological evaluation of novel MAO-A inhibitors targeting lung cancer

S Bardaweel, R Aljanabi, D Sabbah, K Sweidan - Molecules, 2022 - mdpi.com
Lung cancer is one of the most common causes of cancer-related deaths worldwide.
Monoamine Oxidase-A (MAO-A) enzyme mediates the production of reactive oxygen …